Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001104659-14-045832
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-06-13 10:13:13
Reporting Period:
2014-06-11
Filing Date:
2014-06-13
Accepted Time:
2014-06-13 10:13:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1428522 Radius Health Inc. RDUS Blank Checks (6770) 800145732
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1575745 Morana Jovan-Embiricos C/o Radius Health, Inc.
201 Broadway, 6Th Floor
Cambridge MA 02139
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-06-11 1,794,983 $0.00 1,794,983 No 4 C Indirect By Fund
Common Stock Acquisiton 2014-06-11 871,851 $0.00 871,851 No 4 C Indirect By Fund
Common Stock Acquisiton 2014-06-11 587,500 $8.00 587,500 No 4 P Indirect By Fund
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect By Fund
No 4 C Indirect By Fund
No 4 P Indirect By Fund
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B-2 Convertible Preferred Stock Disposition 2014-06-11 227,938 $0.00 1,794,983 $0.00
Common Stock Series B-2 Convertible Preferred Stock Disposition 2014-06-11 110,713 $0.00 871,851 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,557,328 Indirect By Fund
Footnotes
  1. The securities reported reflect (i) the total number of shares of common stock issued pursuant to the conversion of Series B-2 Convertible Preferred Stock (the "Series B-2 Stock") previously reported, (ii) a 1 for 2.28 reverse stock split, effected by the Issuer on 4/24/14 (the "Stock Split"), and (iii) all accrued dividends on the Series B-2 Stock paid in shares of common stock in connection with such conversion.
  2. The reported securities are owned directly by F2 Bioscience IV L.P. ("F2 Bioscience IV"). F2 Bioscience IV GP Ltd. is the General Partner of F2 Bioscience IV. The members of F2 Bioscience IV GP Ltd are Katherine Priestley and Globeways Holdings Limited. The reporting person is a beneficial owner of Globeways Holdings Limited. The reporting person disclaims beneficial ownership of the securities reported herein except to the extent of her pecuniary interest therein.
  3. The reported securities are owned directly by F2 Bio Ventures V L.P. ("F2 Bio"). F2 Bio Ventures GP Ltd is General Partner of F2 Bio. The sole member of F2 Bio Ventures GP Ltd is Globeways Holdings Limited. The reporting person is a beneficial owner of Globeways Holdings Limited. The reporting person disclaims beneficial ownership of the securities reported herein except to the extent of her pecuniary interest therein.
  4. The reported securities are owned directly by F2 Bioscience VI L.P. ("F2 Bioscience VI"). F2 Bioscience IV GP Ltd. is the General Partner of F2 Bioscience VI. The members of F2 Bioscience IV GP Ltd are Katherine Priestley and Globeways Holdings Limited. The reporting person is a beneficial owner of Globeways Holdings Limited. The reporting person disclaims beneficial ownership of the securities reported herein except to the extent of her pecuniary interest therein.
  5. The reported securities are owned directly by F2 Bioscience III, L.P. ("F2 Bioscience III"). F2 Biosciences GP Ltd. ("F2 GP") is the General Partner of F2 Bioscience III. The reporting person is a member of F2 GP. The reporting person disclaims beneficial ownership of the securities reported herein except to the extent of her pecuniary interest therein.
  6. Prior to its automatic conversion into common stock upon the closing of the Issuer's initial public offering on June 11, 2014 (the "Closing Date"), the Series B-2 Stock was convertible at any time, at the holder's election and had no expiration date. On the Closing Date, the Series B-2 Stock was automatically converted into common stock on a 7.678 to 1 basis (which conversion ratio is reflective of the Stock Split), plus accrued dividends on the Series B-2 Stock payable in shares of common stock in connection with such conversion.